Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria | Zendy

Michael D. Tharp | Zendy; Jonathan A. Bernstein | Zendy; Abhishek Kavati | Zendy; Benjamin Ortiz | Zendy; Karen MacDonald | Zendy; Kris Denhaerynck | Zendy; Ivo Abraham | Zendy; Christopher S. Lee | Zendy

Open Access

Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria

Author(s) -

Michael D. Tharp,

Jonathan A. Bernstein,

Abhishek Kavati,

Benjamin Ortiz,

Karen MacDonald,

Kris Denhaerynck,

Ivo Abraham,

Christopher S. Lee

Publication year - 2018

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2018.3447

Subject(s) - omalizumab , medicine , observational study , adverse effect , data extraction , medline , meta analysis , chronic urticaria , pediatrics , immunoglobulin e , immunology , antibody , political science , law

Omalizumab is indicated for the management of chronic idiopathic urticaria (CIU) (also known as chronic spontaneous urticaria) in adolescents and adults with persistent hives not controlled with antihistamines. The effectiveness of omalizumab in the real-world management of CIU is largely unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research